A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors-Reference-Cited by-同舟云学术

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Published:2015-10-21 Issue:6 Volume:22 Page:1348-1355
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Papadopoulos Kyriakos P.,Kelley Robin Kate,Tolcher Anthony W.,Razak Albiruni R. Abdul,Van Loon Katherine,Patnaik Amita,Bedard Philippe L.,Alfaro Ariceli A.,Beeram Muralidhar,Adriaens Lieve,Brownstein Carrie M.,Lowy Israel,Kostic Ana,Trail Pamela A.,Gao Bo,DiCioccio A. Thomas,Siu Lillian L.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

2. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09

3. Differential expression of angiogenesis-related genes ‘VEGF’ and ‘angiopoietin-1’ in metastatic and EMAST-positive colorectal cancer patients;Scientific Reports;2024-05-08

4. Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations;Stroke;2024-05

5. Exploring Current Molecular Targets in the Treatment of Neovascular Age-Related Macular Degeneration toward the Perspective of Long-Term Agents;International Journal of Molecular Sciences;2024-04-17